Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives.

Expert Review of Anticancer Therapy
Giulia SartoriSara Pilotto

Abstract

Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, acting as an irreversible and multitarget blocker of ErbB family members. Afatinib is currently approved for advanced non-small-cell lung cancer (NSCLC) harboring common and uncommon sensitizing EGFR mutations and for squamous NSCLC patients progressing after first-line platinum-based chemotherapy. This review summarizes the efficacy and safety profile of afatinib compared with chemotherapy and other EGFR TKIs, in order to evaluate its characteristics and potential role in the increasingly complex treatment landscape of EGFR-mutant lung cancer. Future perspectives and innovative drug combinations are also discussed. Afatinib has been demonstrated to improve efficacy and quality of life compared with chemotherapy with a managed toxicity profile. However, in recent years, the increasing availability of different treatment options for advanced EGFR-mutant NSCLC has made the current treatment scenario more complicated, with an increasing need of new and deeper scientific data. In this light, the identification and validation of potential clinicopathological and/or molecular predictors of benefit, as well as the clarification of resist...Continue Reading

References

Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy A YapRuth Plummer
Dec 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardVincent A Miller
Apr 19, 2011·Journal of Immunotherapy·Hyunsu KimChi-Dug Kang
Dec 28, 2011·Cancer Chemotherapy and Pharmacology·Peter StopferThomas Ebner
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Feb 14, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J De GrèveD Schallier
Aug 14, 2012·The Journal of Pharmacology and Experimental Therapeutics·Flavio SolcaGuenther R Adolf
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James Chih-Hsin YangLecia V Sequist
Feb 14, 2014·Cancer Chemotherapy and Pharmacology·Matthias FreiwaldAlexander Staab
Jun 8, 2014·Cancer Chemotherapy and Pharmacology·David SchnellRüdiger Koenen
Sep 24, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Petra HoffknechtUNKNOWN Afatinib Compassionate Use Consortium (ACUC)
Feb 16, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jacques De GrèveJohan Vansteenkiste
Feb 17, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Deepa RangachariDaniel B Costa
May 2, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sarayut L GeaterYi-Long Wu
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Nov 13, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Bob T LiNick Pavlakis
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MazièresO Gautschi
Dec 10, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M SchulerUNKNOWN LUX-Lung 5 Investigators
Jan 3, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Bob T LiMaria E Arcila
Jan 30, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Martin SchulerJames C-H Yang
Mar 15, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Li-Yang ChenPan-Chyr Yang
Jul 21, 2016·European Journal of Drug Metabolism and Pharmacokinetics·Sabrina WiebeSven Wind

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Review of Anticancer Therapy
Prantesh JainNeelesh Sharma
BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Vera Hirsh
Drugs
Rosselle T Dungo, Gillian M Keating
© 2022 Meta ULC. All rights reserved